One of the better articles we've seen lately comes from USA Today, explaining what is likely to happen to patients taking GLP-1 drugs since the FDA declared the semaglutide shortage over. (Of course it quoted APC — both CEO Scott Brunner and Pharmacy Compounding Foundation Chair Jenn Burch.)
"These discounted versions of popular weight-loss drugs are going away: What to know" focuses on the transition from compounded drugs to their brand-name counterparts without editorializing about how the FDA (may have) acted too soon in its shortage-ending declaration. 'How will patients afford it?' is the overarching question — and that's one of ours, too.